PH12015502679A1 - Methods of treatment and compositions with xanthine oxidase inhibitors - Google Patents

Methods of treatment and compositions with xanthine oxidase inhibitors

Info

Publication number
PH12015502679A1
PH12015502679A1 PH12015502679A PH12015502679A PH12015502679A1 PH 12015502679 A1 PH12015502679 A1 PH 12015502679A1 PH 12015502679 A PH12015502679 A PH 12015502679A PH 12015502679 A PH12015502679 A PH 12015502679A PH 12015502679 A1 PH12015502679 A1 PH 12015502679A1
Authority
PH
Philippines
Prior art keywords
methods
xanthine oxidase
patient
compositions
treatment
Prior art date
Application number
PH12015502679A
Other languages
English (en)
Inventor
Gunawardhana Lhanoo
Gupte Vijay
Naik Himanshu
Mayer Michael
Komatsu Kanji
Original Assignee
Teijin Pharma Ltd
Takeda Pharmaceuticals Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd, Takeda Pharmaceuticals Usa Inc filed Critical Teijin Pharma Ltd
Publication of PH12015502679A1 publication Critical patent/PH12015502679A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH12015502679A 2013-05-31 2015-12-01 Methods of treatment and compositions with xanthine oxidase inhibitors PH12015502679A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361829759P 2013-05-31 2013-05-31
US201361839609P 2013-06-26 2013-06-26
PCT/US2014/040286 WO2014194226A2 (en) 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors

Publications (1)

Publication Number Publication Date
PH12015502679A1 true PH12015502679A1 (en) 2016-03-07

Family

ID=50983231

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015502679A PH12015502679A1 (en) 2013-05-31 2015-12-01 Methods of treatment and compositions with xanthine oxidase inhibitors

Country Status (9)

Country Link
US (2) US20140357683A1 (enExample)
JP (2) JP2016520133A (enExample)
CN (1) CN105579037A (enExample)
CA (1) CA2913755A1 (enExample)
MX (1) MX2015016494A (enExample)
PH (1) PH12015502679A1 (enExample)
SG (2) SG11201509738RA (enExample)
TW (1) TW201536284A (enExample)
WO (1) WO2014194226A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017072699A1 (en) * 2015-10-28 2017-05-04 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
CN105769766B (zh) * 2016-03-24 2018-07-06 长沙佰顺生物科技有限公司 一种托匹司他纳米乳及其制备方法
JP7108384B2 (ja) * 2016-07-13 2022-07-28 日本ケミファ株式会社 ２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の口腔内崩壊錠
EP3957629B1 (en) 2016-07-18 2023-09-06 Arthrosi Therapeutics, Inc. Process for making deuterated hydroxy-benzbromarone and intermediates thereof
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
KR20210100677A (ko) 2018-12-06 2021-08-17 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
AU2020287549A1 (en) * 2019-06-04 2022-01-27 Nippon Chemiphar Co., Ltd. Therapeutic for gout or hyperuricemia
JP7668386B2 (ja) * 2021-06-15 2025-04-24 エルジー・ケム・リミテッド １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物
CN115252567A (zh) * 2022-07-08 2022-11-01 广西纯正堂制药有限公司 非布司他渗透泵缓释片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5544163A (en) 1994-03-08 1996-08-06 Excel, Inc. Expandable telecommunications system
ES2505690T3 (es) 2002-03-28 2014-10-10 Teijin Pharma Limited Preparación sólida que contiene una forma única de cristal de un derivado de ácido tiazolcarboxílico
DK1757610T3 (da) 2004-06-14 2011-08-01 Nippon Chemiphar Co Kondenseret pyrimidinderivat og xanthinoxidaseinhibitor
JP5040656B2 (ja) 2005-10-07 2012-10-03 アステラス製薬株式会社 トリアリールカルボン酸誘導体
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
KR101772963B1 (ko) 2009-03-31 2017-08-31 깃세이 야쿠힌 고교 가부시키가이샤 인돌리진 유도체 및 그 의약용도
CN101773498B (zh) * 2009-12-30 2012-06-20 青岛黄海制药有限责任公司 一种含有非布司他的口服缓控释制剂的制备方法
ES2669184T3 (es) * 2010-06-16 2018-05-24 Takeda Pharmaceuticals U.S.A., Inc. Nuevas formas de dosificación de liberación modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa
UY33455A (es) 2010-06-16 2012-01-31 Teijin Pharma Ltd Tableta con núcleo recubierto de liberación controlada
CN102641255A (zh) * 2012-05-08 2012-08-22 南方医科大学 一种治疗痛风的非布索坦渗透泵控释片及其制备方法

Also Published As

Publication number Publication date
JP2016520133A (ja) 2016-07-11
CA2913755A1 (en) 2014-12-04
SG10201709955PA (en) 2018-01-30
US20180311217A1 (en) 2018-11-01
WO2014194226A2 (en) 2014-12-04
US20140357683A1 (en) 2014-12-04
TW201536284A (zh) 2015-10-01
WO2014194226A3 (en) 2015-05-14
JP2019108356A (ja) 2019-07-04
MX2015016494A (es) 2016-11-18
SG11201509738RA (en) 2015-12-30
CN105579037A (zh) 2016-05-11

Similar Documents

Publication Publication Date Title
PH12015502679A1 (en) Methods of treatment and compositions with xanthine oxidase inhibitors
ZA202308496B (en) Pharmaceutical compositions of therapeutically active compounds
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
MX2016016744A (es) Inhibidores de ezh2 para tratar linfomas.
TN2017000554A1 (en) Novel combination for use in the treatment of cancer
PH12016502355A1 (en) Pharmaceutical composition
ZA201700196B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
WO2014134583A3 (en) Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
PH12015501783A1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
NZ735777A (en) Methods and compositions to inhibit symptoms associated with veisalgia
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
IN2014DN08443A (enExample)
MD4475B1 (ro) Utilizare a unei formulări cu administrare orală pentru tratamentul bolilor cardiovasculare
IN2013MU02370A (enExample)
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
AR096513A1 (es) Métodos de tratamiento y composiciones con inhibidores de la xantina oxidasa
MY169877A (en) Treatment of malphigia coccigera on liver cirrhosis
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы
ZA201606135B (en) Pharmaceutical compositions of therapeutically active compounds